← Back to IPO List

Hemab Therapeutics

Last updated: May 4, 2026
Ticker
COAG
Exchange
NYSE
IPO Date
Pending
Price Range
$16.00 - $18.00
Deal Size
$302 million
View COAG Live Chart on TradingViewAffiliate link — we may earn a commission.

Company Snapshot

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for blood coagulation disorders. The company aims to address significant unmet medical needs by discovering and commercializing treatments for patients suffering from serious bleeding and thrombotic diseases. Their lead asset, sutacimig (HMB-001), is currently in clinical development for the prophylactic treatment of Glanzmann thrombasthenia.

Founded
2026

Key Financials

Metric20252024
RevenueNot providedNot provided
Adjusted Net Loss-$63.9M-$48.7M

Balance Sheet

Cash & Equivalents
$88.0M

Implied Valuation at Midpoint

Market Cap
$667M

Based on price range midpoint and most recent fiscal year data.

S-1 Highlights

Market & Competition

The company operates in the biotechnology industry, specifically targeting blood coagulation disorders. Hemab Therapeutics competes with companies such as Novo Nordisk A/S and Genmab A/S.

Use of Proceeds

Proceeds from the IPO are expected to be used to fund clinical trials, research and development, and general corporate purposes.

Key Risk Factors

  • ●The company relies on third parties for clinical trials and manufacturing, which may lead to delays or failures in development.
  • ●Material weaknesses in internal control over financial reporting could impact the company's ability to produce timely and accurate financial statements.

Deal Structure

Primary Shares
11,764,706 shares
Shares Outstanding
39,207,616 shares
Post-IPO Float
42.8%
Lock-up
180 days
Lead Underwriters
Goldman Sachs & Co. LLC, Jefferies, Evercore ISI, Wedbush PacGrow

Reported Broker Availability

No broker information available yet

Check back later for updates

Reported by users or publicly disclosed. Information is for reference only.

Important Links & Filings

COAG Live Chart on TradingView →SEC S-1 Filing →
Important: Information presented on this website is aggregated from publicly available sources and voluntary user submissions. It is provided for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. IPO access and availability may vary by broker and is not guaranteed; always verify details directly with your broker before making any investment decisions. We are not affiliated with, endorsed by, or acting on behalf of any broker-dealers, underwriters, or issuing companies. Some links to broker platforms may be affiliate links, and we may earn a commission if you open an account through those links. See full disclaimer for additional information.